Cargando…
Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer
BACKGROUND: Follistatin (FST) is an intrinsic inhibitor of activin, a member of the transforming growth factor-β superfamily of ligands. The prognostic value of FST and its family members, the follistatin-like (FSTL) proteins, have been studied in various cancers. However, these studies, as well as...
Autores principales: | Seachrist, Darcie D., Sizemore, Steven T., Johnson, Emhonta, Abdul-Karim, Fadi W., Weber Bonk, Kristen L., Keri, Ruth A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460489/ https://www.ncbi.nlm.nih.gov/pubmed/28583174 http://dx.doi.org/10.1186/s13058-017-0857-y |
Ejemplares similares
-
KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene
por: Roberts, Melyssa S., et al.
Publicado: (2020) -
Up to your NEK2 in CIN
por: Seachrist, Darcie D., et al.
Publicado: (2021) -
FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer
por: Seachrist, Darcie D., et al.
Publicado: (2021) -
Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy
por: Cuellar-Vite, Leslie, et al.
Publicado: (2022) -
The PML1-WDR5 axis regulates H3K4me3 marks and promotes stemness of estrogen receptor-positive breast cancer
por: Kao, Hung-Ying, et al.
Publicado: (2023)